30
Jun

The FDA has handed out its third rejection of a new, inhalable migraine therapy Allergan had hoped could be used to help fend off Valeant’s buyout bid. The big biotech did get some good news, though, announcing that the agency approved Ozurdex for diabetic macular degeneration.

…read more

Source: FDA hands out its third rejection for Allergan’s migraine drug Semprana

    

0 No comments